Effects of Peppermint Oil in Mild-moderate Hypertension.

Phase

N/A

Condition

Stress

Circulation Disorders

Williams Syndrome

Treatment

Placebo

Peppermint oil

Clinical Study ID

NCT05561543

Peppermint oil hypertension

Ages 18-65
All Genders

Study Summary

Cardiovascular and associated hypertensive diseases are the leading health burden and cause of mortality worldwide; therefore, the necessity for effective interventions is paramount. Dietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. Our previous randomized trial has shown that oral peppermint can improving systolic blood pressure and other cardiovascular/ blood lipids in healthy individuals. However, to date, no research has explored this using a placebo randomized intervention in patients with hypertension.

Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in participants with mild-moderate hypertension.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Aged from 18-65 years
Systolic blood pressure 120 to 139 mmHg
Not taking prescribed medicine for blood pressure management
have the ability to complete written questionnaires independently
Able to provide informed consent

Exclusion

Exclusion Criteria:

diagnosed diabetes mellitus
known cardiovascular disease or clinically significant cardiovascular comorbidity,including coronary heart disease, symptomatic heart failure, clinically significantarrhythmia, or a history of stroke or transient ischaemic attack within the previous 6 months
known or suspected secondary hypertension, including renal, renovascular, orendocrine causes
known clinically significant renal impairment or severe hepatic disease
evidence or history of severe hypertension related target organ damage requiringspecialist management
pregnant or lactating women
allergy to peppermint
habitual consumption of peppermint products
regular consumption of antioxidant supplements
body mass index larger than 40.0 kg/m²
current enrolment in other clinical trials or use of other external therapies likelyto influence outcomes
condition(s) likely to compromise informed consent, protocol compliance, or outcomeassessment, including severe psychiatric illness, cognitive impairment, or activesubstance or alcohol misuse.

Study Design